Filing Details

Accession Number:
0001127602-22-022782
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-21 16:50:59
Reporting Period:
2022-09-19
Accepted Time:
2022-09-21 16:50:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
313143 Haemonetics Corp HAE Surgical & Medical Instruments & Apparatus (3841) 042882273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1699629 L Michelle Basil 125 Summer Street
Boston MA 02110
Evp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-09-19 3,464 $38.43 38,859 No 4 M Direct
Common Stock Acquisiton 2022-09-19 4,213 $41.64 43,072 No 4 M Direct
Common Stock Acquisiton 2022-09-19 1,011 $56.57 44,083 No 4 M Direct
Common Stock Disposition 2022-09-19 11,448 $78.36 32,635 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2022-09-19 3,464 $0.00 3,464 $38.43
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2022-09-19 4,213 $0.00 4,213 $41.64
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2022-09-19 1,011 $0.00 1,011 $56.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-03-06 2024-03-06 No 4 M Direct
0 2018-06-06 2024-06-06 No 4 M Direct
12,553 2028-05-18 No 4 M Direct
Footnotes
  1. Transaction pursuant to an existing 10b5-1 trading plan.
  2. This number includes unvested restricted stock units ("RSUs") previously reported.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.